5604 results
Refine Your Search
Predictors of response to therapy in A051902, a US Intergroup study of duvelisib+CHO(E)P vs CC-486+CHO(E)P vs CHO(E)P in peripheral T-cell lymphoma
We are evaluating if adding duvelisib or azacitidine to standard chemotherapy increases the complete remission rate compared to chemotherapy alone in …
Tycel Phillips
I am a physician employed at the University of Michigan who specializes in the management of patients with a very specific blood cancer called lymphom…
Stratified treatment of newly diagnosed MCL based on the presence or absence of high risk features utilizing non-cytotoxic agents.
We believe that regimens without chemotherapy can induce significant and durable remissions in patients with Mantle cell lymphoma (MCL). We will confi…
Thomas LeBlanc
I am a oncologist and palliative care physician, Associate Professor of Medicine in the Duke University School of Medicine, and member of the Duke Ca…
Patient Experience Research and Palliative Care Integration in Malignant Hematology
My research aims to improve the patient and caregiver experience of blood cancer care. To achieve this, I conduct trials of integrated palliative care…
Understanding the clonal origin, evolution, and progression of myeloid malignancies
The overarching focus of my research is to understand the clonal origin, evolution, and progression of myeloid malignancies and biological and clinica…
Koichi Takahashi
Koichi Takahashi, MD, PhD is Associate Professor in the Departments of Leukemia and Genomic Medicine at The University of Texas MD Anderson Cancer Cen…
Luca Busino
The molecular mechanisms of cell proliferation and the field of Ubiquitin Proteasome System (UPS) have always been our main area of interest and fasci…
Relevance of ubiquitin dependent proteolysis in diffuse large B-cell lymphoma
The goal of this proposal is to investigate the significance of genes of the ubiquitin proteasome system (UPS) that are mutated in Diffuse Large Lymp…
Faron Pharmaceuticals Announces the Private Placement of EUR 5 Million, Including LLS TAP
TURKU, FINLAND / BOSTON, MA, June , - Faron Pharmaceuticals Ltd (First North: FARON, AIM: FARN), a clinical stage biopharmaceutical company focused o…
Paul
I have been very active with LLS for over years including: serving on the Wisconsin Chapter Board and Leadership Development Committee; fundraising f…
Living with Myeloma
Coleman Lindsley
Dr. Lindsley is an Assistant Professor of Medicine at Harvard Medical School and Cancer Institute. He received his M.D. and Ph.D.
Genetic pathways of myeloid transformation and treatment response
Our central goal is to improve clinical outcomes in patients with myeloid malignancies through developing an enhanced mechanistic understanding of dis…
Julia Maxson
Dr. Maxson is an assistant professor in the Knight Cancer Institute, where she investigates the cellular and molecular changes that cause myeloid leuk…
Targeting the interplay between signaling and transcriptional dysfunction in myeloid leukemias
Our research program is focused on understanding the intersection between signaling and transcriptional dysfunction in myeloid leukemias. We leverage …
Yibin Yang
I completed my Ph.D. training with Dr. Michelle Kelliher at the University of Massachusetts Medical School, studying the signal transduction pathways…
Analysis and therapeutic targeting of the immune regulatory and ubiquitination pathways in Anaplastic Large Cell Lymphoma and Hodgkin Lymphoma
My lab is focused on the immune regulatory mechanisms and machinery in lymphoma. We have established multiple screening technologies and animal mode…
Genomic interrogation of high-risk myeloid neoplasms to identify new therapies
The goal of my research program is to improve the outcomes for patients with myeloid blood cancers, particularly those with loss of chromosome or C…
Megan McNerney
Dr. Megan McNerney, MD/PhD, is an Associate Professor in the Departments of Pathology and Pediatrics at The University of Chicago. She is a cancer gen…
Daniel Herranz
A PharmD by training, I then obtained my PhD guided by Dr. Manuel Serrano at the CNIO studying Sirt1 role in metabolism and cancer, which led to and…
Therapeutic exploitation of novel mouse models and metabolic interventions in leukemia
Our research program aims to gain a deeper understanding of the pathobiology of and HSTL.To this end, we will use novel mouse models, techniques and…
Investigating and targeting the histone acetylation reader protein ENL in acute leukemias
Leukemia often results from aberrant gene expression caused by epigenetic alterations. Previously we discovered a novel histone acetylation reader dom…
Hong Wen
I am an Associate Professor in the Department of Epigenetics at Van Andel Institute. My research is focused on epigenetic regulation of gene expressio…
A Phase I/II Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
SIRPα+ macrophages mediate resistance to lenalidomide in lymphoma, limiting the activity of immunotherapy for these patients. Therefore, we propose a…
Cruz
Cancer almost killed me, but more importantly, it made me who I am and who I will become. I was diagnosed with acute myeloid leukemia (AML) at Texas C…